Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors

Are you keeping a close watch on ZIVO Bioscience, Inc. (ZIVO) and wondering about its financial stability? Let's delve into the numbers that matter most. As of December 31, 2024, the company's trailing 12-month revenue stood at $157K, a notable increase from $27.65K the previous year. However, the company reported a net loss of $13.38 million, which is significantly higher than the $7.78 million loss in 2023. With total assets amounting to $1.643 million and a market cap of $56.4 million as of April 15, 2025, what does this mean for potential investors? Keep reading to uncover key insights into ZIVO's financial health and make informed decisions.

ZIVO Bioscience, Inc. (ZIVO) Revenue Analysis

As of the latest information available, ZIVO Bioscience, Inc. (ZIVO) is a development-stage company focused on the research and development of therapeutic molecules derived from algae. Given its developmental stage, the company has historically relied on investment and funding rather than product sales for its revenue.

Details on ZIVO Bioscience, Inc.'s revenue streams are limited due to its current operational phase. As a development-stage company, ZIVO Bioscience, Inc. has not yet generated substantial revenue from product sales. Its financial viability depends on securing investments, grants, and forming potential partnerships to fund its research and development activities.

Here's a breakdown of what impacts ZIVO's financial picture:

• Primary Revenue Sources: Currently, ZIVO's main financial inputs come from investments, grants, and other funding activities.
• Year-over-year Revenue Growth Rate: It is difficult to pinpoint a specific growth rate because the company is pre-revenue. Instead, financial performance is closely tied to successful fundraising and managing operating expenses.
• Contribution of Business Segments: Since ZIVO is focused on research and development, there are no distinct business segments contributing to revenue in the traditional sense.
• Changes in Revenue Streams: Any significant changes would likely involve obtaining new funding sources or forming strategic partnerships that could provide financial support.

For a deeper dive into the investors and rationale behind supporting ZIVO Bioscience, Inc., check out this related article: Exploring ZIVO Bioscience, Inc. (ZIVO) Investor Profile: Who’s Buying and Why?

The absence of substantial revenue from product sales emphasizes the importance of monitoring ZIVO’s ability to secure funding and manage its expenditures effectively. Investors should closely watch for announcements regarding partnerships, grants, and other financial arrangements, as these will be critical to ZIVO’s long-term prospects.

The following table illustrates the financial dynamics of a similar development-stage company. Note that this is an example and not specific to ZIVO, but it reflects common revenue and expense patterns.

ZIVO Bioscience, Inc. (ZIVO) Profitability Metrics

Analyzing ZIVO Bioscience, Inc. (ZIVO)'s profitability involves examining several key metrics to understand its financial health and operational efficiency. Profitability metrics offer insights into how well a company generates profit from its revenues and assets.

Here's a breakdown of essential profitability aspects:

• Gross Profit: This is the profit a company makes after deducting the costs associated with producing and selling its products or services.
• Operating Profit: This metric reflects the profit earned from a company's core business operations, excluding interest and taxes.
• Net Profit: Often referred to as the bottom line, net profit is the profit remaining after all expenses, including interest, taxes, and other costs, have been deducted from revenue.

To assess ZIVO Bioscience, Inc. (ZIVO)'s financial performance, it's crucial to consider these profit margins:

• Gross Profit Margin: Indicates the percentage of revenue remaining after subtracting the cost of goods sold.
• Operating Profit Margin: Shows the percentage of revenue remaining after deducting operating expenses.
• Net Profit Margin: Represents the percentage of revenue that translates into net profit.

Unfortunately, specific financial figures for the fiscal year 2024 regarding ZIVO Bioscience, Inc. (ZIVO)'s gross profit, operating profit, and net profit margins are not available in the provided search results. Therefore, an accurate analysis of these metrics and a comparison with industry averages cannot be conducted at this time.

When evaluating operational efficiency, investors often look at factors such as cost management and gross margin trends. Effective cost management can lead to improved profitability, while positive trends in gross margin indicate that the company is becoming more efficient in its production and sales processes.

Without up-to-date financial data for 2024, a comprehensive assessment of ZIVO Bioscience, Inc. (ZIVO)'s current profitability and operational efficiency is not feasible. For detailed financial analysis, refer to the Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors.

ZIVO Bioscience, Inc. (ZIVO) Debt vs. Equity Structure

Understanding how ZIVO Bioscience, Inc. (ZIVO) finances its operations and growth is crucial for investors. This involves examining the company's debt levels, its debt-to-equity ratio, and how it strategically uses debt and equity to fund its activities. For additional insights, check out Exploring ZIVO Bioscience, Inc. (ZIVO) Investor Profile: Who’s Buying and Why?.

As of the fiscal year 2024, a detailed breakdown of ZIVO Bioscience, Inc. (ZIVO)'s debt structure is essential for assessing its financial risk and stability. While specific figures for long-term and short-term debt require up-to-date financial statements, understanding these components is vital:

• Short-Term Debt: This includes obligations due within one year, such as accounts payable, short-term loans, and the current portion of long-term debt.
• Long-Term Debt: This encompasses obligations due beyond one year, such as bonds, long-term loans, and other financing arrangements.

Analyzing the composition of debt helps investors determine the company's ability to meet its immediate and future obligations. For instance, a high level of short-term debt relative to current assets may indicate liquidity issues.

The debt-to-equity ratio is a key metric for evaluating ZIVO Bioscience, Inc. (ZIVO)'s financial leverage. It compares the total debt to shareholders' equity, indicating the proportion of debt used to finance assets relative to the value of equity. While pinpointing the exact ratio necessitates the latest financial data, here’s how to interpret it:

A high debt-to-equity ratio suggests that the company relies more on debt, which can amplify returns during profitable times but also increases financial risk during downturns. Conversely, a low debt-to-equity ratio indicates a more conservative approach, with a greater reliance on equity financing.

Industry standards vary, but comparing ZIVO Bioscience, Inc. (ZIVO)'s ratio to its peers provides valuable context. Generally, a ratio around 1.0 is considered average, but what is acceptable depends on the industry's capital intensity and stability.

Staying informed about ZIVO Bioscience, Inc. (ZIVO)'s recent debt issuances, credit ratings, and refinancing activities is crucial for assessing its financial strategy and risk profile. Here’s why:

• Debt Issuances: New debt issuances can provide capital for growth initiatives but also increase the company’s debt burden.
• Credit Ratings: Ratings from agencies like Standard & Poor's, Moody's, and Fitch reflect the company's creditworthiness and ability to repay debt.
• Refinancing: Refinancing activities can lower interest rates or extend debt maturities, improving cash flow and financial flexibility.

Understanding these activities helps investors gauge the company's financial management and its outlook on future growth and stability.

ZIVO Bioscience, Inc. (ZIVO) strategically balances debt financing and equity funding to optimize its capital structure. Debt financing can provide a cost-effective way to fund growth, especially when interest rates are low. However, it also increases financial risk. Equity funding, on the other hand, dilutes ownership but strengthens the balance sheet.

The optimal balance depends on various factors, including the company's growth prospects, risk tolerance, and market conditions. Companies in the biotechnology industry, like ZIVO Bioscience, Inc. (ZIVO), often rely on equity funding due to the high risk and long development cycles associated with their products.

ZIVO Bioscience, Inc. (ZIVO) Liquidity and Solvency

Assessing the liquidity of ZIVO Bioscience, Inc. (ZIVO) involves examining several key financial metrics and statements. These include the current and quick ratios, working capital trends, and cash flow statements. A thorough analysis of these elements provides insights into the company's ability to meet its short-term obligations and overall financial health.

The current and quick ratios are essential indicators of a company's liquidity position. The current ratio measures a company's ability to pay off its current liabilities with its current assets. The quick ratio, also known as the acid-test ratio, excludes inventory from current assets to provide a more conservative view of a company's ability to meet its short-term liabilities. A higher ratio generally indicates a stronger liquidity position, suggesting the company is more capable of covering its short-term obligations.

Analysis of working capital trends is also crucial. Working capital, calculated as current assets minus current liabilities, represents the funds available for a company's day-to-day operations. Monitoring the changes in working capital over time can reveal whether a company's liquidity is improving or deteriorating. A positive and increasing working capital balance typically indicates a healthy liquidity position, while a negative or decreasing balance may signal potential liquidity issues.

Cash flow statements provide a comprehensive overview of a company's cash inflows and outflows, categorized into operating, investing, and financing activities. Analyzing the trends in each of these categories can offer valuable insights into a company's liquidity. Positive cash flow from operating activities indicates that the company is generating sufficient cash from its core business operations to cover its expenses and invest in future growth. Negative cash flow from investing activities may suggest that the company is making significant investments in capital expenditures, while negative cash flow from financing activities could indicate that the company is repaying debt or distributing dividends.

Potential liquidity concerns or strengths can be identified by examining these financial metrics and statements. For example, a low current or quick ratio, a decreasing working capital balance, or negative cash flow from operating activities may raise concerns about a company's ability to meet its short-term obligations. Conversely, a high current or quick ratio, an increasing working capital balance, or positive cash flow from operating activities may indicate a strong liquidity position.

For additional insights into ZIVO Bioscience, Inc. (ZIVO) financial health, you can explore Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors.

ZIVO Bioscience, Inc. (ZIVO) Valuation Analysis

Determining whether ZIVO Bioscience, Inc. (ZIVO) is overvalued or undervalued requires a multifaceted approach, incorporating various financial ratios, stock performance analysis, and analyst opinions. Key metrics to consider include price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA). However, given ZIVO's current financial status, some of these metrics might not be directly applicable or meaningful.

Here’s a breakdown of factors to consider:

• Price-to-Earnings (P/E) Ratio: This ratio is typically used to compare a company's stock price to its earnings per share. As of the latest available data, ZIVO Bioscience currently has no earnings, rendering the P/E ratio inapplicable.
• Price-to-Book (P/B) Ratio: The P/B ratio compares a company's market capitalization to its book value of equity. As of the third quarter of 2024, ZIVO's Price to Book ratio is 0.92. A ratio below 1.0 could suggest the stock is undervalued relative to its assets.
• Enterprise Value-to-EBITDA (EV/EBITDA): This ratio compares a company's enterprise value to its earnings before interest, taxes, depreciation, and amortization (EBITDA). This metric is useful for evaluating companies with significant debt or those that are not yet profitable. As ZIVO Bioscience currently has negative EBITDA, this metric may not be particularly informative at this time.

Analyzing ZIVO Bioscience's stock price trends over the last 12 months provides additional context. As of April 21, 2025, it's important to review the stock's performance to understand market sentiment and volatility. Recent data indicates:

• 52-Week Range: The 52-week high was $4.90 and the 52-week low was $0.87.
• Current Price: $1.25.

These figures show substantial price fluctuation, reflecting the speculative nature of biotechnology stocks and the impact of company-specific news and broader market trends.

Dividend yield and payout ratios are not applicable for ZIVO Bioscience, as the company does not currently offer dividends. This is common for growth-oriented companies that reinvest earnings to fund research and development. Analyst consensus on ZIVO Bioscience stock valuation varies. As of November 2024, analysts ratings include:

• Taglich Brothers: Reiterated a 'Buy' rating with a price target of $11.00 on November 15, 2024.
• Maxim Group: Reiterated a 'Buy' rating with a price target of $7.00 on November 15, 2024.

These ratings suggest a positive outlook, but it's important to consider that analyst opinions can change and should not be the sole basis for investment decisions. The table below summarizes key valuation considerations for ZIVO Bioscience, Inc. (ZIVO):

Considering these factors, assessing whether ZIVO Bioscience is overvalued or undervalued requires a comprehensive understanding of its financial position, market sentiment, and future growth prospects. Investors should conduct thorough due diligence and consider their own risk tolerance and investment objectives before making any decisions.

To gain further insights into the company's strategic direction, see: Mission Statement, Vision, & Core Values of ZIVO Bioscience, Inc. (ZIVO).

ZIVO Bioscience, Inc. (ZIVO) Risk Factors

ZIVO Bioscience, Inc. (ZIVO) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges and external market dynamics. Understanding these factors is crucial for investors assessing the company's prospects.

Here’s an overview of key risks:

• Industry Competition: The biotechnology industry is intensely competitive. ZIVO faces competition from larger, more established companies with greater financial and technical resources. This competition could hinder ZIVO's ability to successfully develop and commercialize its products.
• Regulatory Changes: The development and commercialization of pharmaceutical products are subject to extensive regulation by governmental authorities, including the FDA in the United States. Changes in regulatory requirements or delays in obtaining necessary approvals could adversely affect ZIVO's operations and financial condition.
• Market Conditions: Unfavorable market conditions, such as economic downturns or changes in investor sentiment towards the biotechnology industry, could negatively impact ZIVO's ability to raise capital and maintain its stock price.

Operational, financial, and strategic risks are often detailed in ZIVO Bioscience, Inc.'s (ZIVO) earnings reports and filings. These documents provide insights into the specific challenges the company is currently addressing.

Examples of these risks include:

• Operational Risks: These include challenges related to research and development, manufacturing, and supply chain management. Delays or failures in any of these areas could disrupt ZIVO's operations and increase costs.
• Financial Risks: ZIVO may face risks related to its ability to secure funding, manage its cash flow, and maintain financial stability. These risks are particularly relevant for biotechnology companies that require significant capital investment to fund their research and development activities.
• Strategic Risks: These involve risks related to ZIVO's business strategy, such as its ability to successfully identify and pursue new market opportunities, manage its intellectual property, and adapt to changing market conditions.

Mitigation strategies are plans that ZIVO Bioscience, Inc. (ZIVO) may implement to reduce the impact of these risks. While specific mitigation plans can vary depending on the nature of the risk, some common strategies include:

• Diversification: Diversifying its product pipeline and target markets to reduce its reliance on any single product or market.
• Strategic Alliances: Forming partnerships with other companies to share resources, expertise, and risk.
• Risk Management Programs: Implementing comprehensive risk management programs to identify, assess, and mitigate potential risks.
• Insurance: Obtaining insurance coverage to protect against certain types of losses, such as product liability claims or property damage.

For further insights into ZIVO Bioscience, Inc. (ZIVO) financial health, you can explore: Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors

ZIVO Bioscience, Inc. (ZIVO) Growth Opportunities

ZIVO Bioscience, Inc. (ZIVO) faces a landscape ripe with potential for growth, driven by innovative product development, strategic market expansion, and key partnerships. Understanding these factors is crucial for investors assessing the company's future trajectory.

Key growth drivers for ZIVO include:

• Product Innovations: ZIVO's focus on developing novel nutritional ingredients and biologics offers a strong foundation for growth. Successful commercialization of their algae-based products could significantly boost revenue.
• Market Expansion: Expanding into new geographic markets and targeting different customer segments (e.g., animal health, human nutrition) can unlock additional revenue streams.
• Strategic Alliances: Collaborations with research institutions, manufacturing partners, and distribution networks can accelerate product development, reduce costs, and expand market reach.

While specific future revenue growth projections and earnings estimates are subject to market conditions and the success of ZIVO's pipeline, several strategic initiatives could significantly impact the company's financial performance:

Here's a look at potential strategic initiatives:

• Advancing Clinical Trials: Progressing its lead compounds through clinical trials is essential for demonstrating efficacy and safety, which can attract partnerships and investment.
• Securing Regulatory Approvals: Obtaining regulatory approvals for its products in key markets is a critical step towards commercialization and revenue generation.
• Building a Strong Intellectual Property Portfolio: Protecting its innovations through patents and other intellectual property rights is crucial for maintaining a competitive advantage.

ZIVO's competitive advantages that position the company for growth include:

• Proprietary Technology: The company's unique algae-based platform provides a competitive edge in developing novel nutritional and therapeutic products.
• Experienced Management Team: A strong leadership team with expertise in biotechnology, product development, and commercialization is essential for executing the company's growth strategy.
• Growing Demand for Natural Products: The increasing consumer demand for natural and sustainable products creates a favorable market environment for ZIVO's offerings.

For additional insights into ZIVO Bioscience, Inc. (ZIVO) financial health, you can explore: Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors